Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

Appoints Eliot M. Lurier, CPA, as Interim Chief Financial Officer Reaffirms 2023 Financial Guidance BOULDER, Colo., June 06, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc. (NASDAQ:SLGC), a leader in proteomics technology, today announced a Chief Financial Officer transition. Eliot M. Lurier, CPA, is joining the company as Interim CFO while the Company conducts a search for a permanent CFO. Shaun Blakeman has left the company, effective June 5, 2023. Mr. Lurier has over 35 years of experience in financial and leadership positions across the life science industry. He will report directly to the Interim CEO and immediately embed within the finance organization to ensure a seamless transiti

BOULDER, Colo. and SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ:SLGC), a leader in AI data-driven proteomics technology, today announced the appointment of current board member and biotech veteran Troy Cox as Executive Chair to the company's Board of Directors. The current Chair, Chuck Lillis, will remain on the board. Changes are effective as of today, October 17, 2022. Mr. Cox brings over thirty years of experience in the life sciences and biopharmaceuticals industry to his expanded position as Executive Chair of the Board. Mr. Cox was the President and CEO of Foundation Medicine from early 2017 through the acquisition by Roche, valuing Foundation Medicine at $5.3 bill

BOULDER, Colo., Jan. 10, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ:SLGC), a leader in data-driven proteomics technology, today announced that Adam Taich has joined the company as the Chief Business Officer. In this newly created role, Adam will have broad responsibility across SomaLogic's rapidly growing business to drive the company's strategic and business development goals. He will also serve as a member of SomaLogic's Executive Committee. Adam will report to SomaLogic Chief Executive Officer Roy Smythe, M.D. "We are very pleased Adam has joined the SomaLogic team," said SomaLogic Chief Executive Officer Roy Smythe, M.D. "His decades of leadership experience across a broad spectrum o

BOULDER, Colo., Dec. 02, 2021 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ:SLGC), a leader in data-driven proteomics technology, today announced that Steve Mermelstein joined the company as Senior Vice President of Corporate Strategy, Development and Mergers and Acquisitions (M&A). "We are thrilled to welcome Steve to the SomaLogic team," said SomaLogic Chief Executive Officer Roy Smythe, M.D. "His extensive advisory and execution expertise in the life sciences sector, focused primarily on tools and diagnostics, positions us well for successful inorganic growth. I look forward to working with Steve as we continue to rapidly scale our business." Steve has more than 25 years of experience pro

Data to showcase PROphet® platform's machine learning models for predicting therapeutic benefit and immune-related adverse events in non-small cell lung cancer patients treated with immunotherapy BINYAMINA, Israel and CARY, N.C., March 5, 2024 /PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced it will be presenting new results at the American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 5-10, 2024. The oral presentation will feature insights from the company's PROPHETIC trial, to be delivered by Prof. Jarushka Naidoo, consultant medical oncologi

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with SomaLogic (NASDAQ:SLGC) at its Special Meeting of Stockholders. "We are pleased with the outcome of today's Special Meeting and thank our stockholders for their support for this merger," said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "Together with SomaLogic, we will have an expanded platform to better serve our customers and we be

Stockholder Approval Represents Key Milestone Toward Completion of Standard BioTools Transaction Combination Will Create a Diversified Leader in Life Sciences Tools BOULDER, Colo., Jan. 4, 2024 /PRNewswire/ -- SomaLogic, Inc. (NASDAQ:SLGC) ("the Company"), a leader in proteomics technology, today announced that, based on the preliminary vote count provided by its proxy solicitors following the Company's Special Meeting of Stockholders (the "Special Meeting") held earlier today, SomaLogic stockholders voted to approve the transaction with Standard BioTools Inc. (NASDAQ:LAB) ("Standard BioTools"). The SomaLogic Board of Directors issued the following statement: We are grateful for the suppor

Believes All SomaLogic Directors – Robert Barchi, Thomas Carey, Eli Casdin, Troy Cox, Kathy Hibbs, Anne Margulies, Tycho Peterson, Richard Post and Jason Ryan – Have Betrayed Shareholders by Delaying the Special Meeting Five Times so the Board Could Initiate a Covert Vote-Flipping Campaign Encourages Shareholders to Take Note of the Board's Governance Failures and Blatant Abuse of Shareholder Democracy Notes Madryn Has Sent a Litigation Hold to the SomaLogic Board as the Firm Evaluates Legal Options Urges Shareholders Interested in Changing Their Vote and/or Opposing the Merger to Contact Madryn or the Firm's Proxy Solicitor Madryn Asset Management, LP (collectively with its affilia

Believes Two Last-Minute Adjournments of Special Meeting Stem From Fellow Shareholders Recognizing the Deal Consideration Assigns No Value to SomaLogic's Desirable Assets and Represents a Material Discount to Company's Cash Contends Fellow Shareholders Share Concerns About the Combined Entity's Proforma Capital Structure and Governance, Which Would Subordinate Them to Conflicted Insiders Like Hedge Fund Manager Eli Casdin (a Director and Shareholder of Both Companies) Urges All SomaLogic Shareholders to Oppose the Conflict-Ridden Transaction and Reject the Company's Questionable Eleventh-Hour Attempts to Covertly Secure Necessary Votes Madryn Asset Management, LP (collectively with it

Madryn Asset Management, LP ("Madryn Asset Management" and, collectively with its affiliates, "Madryn"), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. ("SomaLogic" or the "Company") (NASDAQ:SLGC), today announced that Egan-Jones Proxy Services ("Egan-Jones"), an independent proxy advisory firm, has recommended shareholders vote AGAINST the proposed merger (the "Proposed Merger" or "Transaction") with Standard BioTools Inc. ("Standard BioTools") (NASDAQ:LAB) at the Company's Special Meeting of Shareholders (the "Special Meeting") on January 4, 2024. In its report, Egan-Jones noted:1 "Egan-Jones views the proposed transaction to be untimely and inadvis

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Both Recommend SomaLogic Stockholders Vote "FOR" Proposed Merger with Standard BioTools BOULDER, Colo., Jan. 2, 2024 /PRNewswire/ -- SomaLogic, Inc. (NASDAQ:SLGC) ("the Company"), a leader in proteomics technology, today sent the following open letter to stockholders urging them to vote "FOR" the value maximizing transaction with Standard BioTools. The full text of the letter is as follows: Dear Fellow Stockholders, Our upcoming special meeting of SomaLogic stockholders to vote on the merger with Standard BioTools is fast approaching. The SomaLogic Board believes that voting "FOR" the transaction represents the best opportunity av

Boston Millennia Partners ("Boston Millennia"), a significant shareholder of SomaLogic (the "Company") (NASDAQ:SLGC) today announced that it intends to vote against the Company's planned merger (the "Merger") with Standard BioTools Inc. (NASDAQ:LAB). View source version on businesswire.com: https://www.businesswire.com/news/home/20231231077712/en/

Highlights That Four SomaLogic Shareholders Have Now Openly Stated Their Intention to Vote "AGAINST" the Proposed Merger with Standard BioTools Urges Fellow Shareholders to Vote "AGAINST" the Proposed Merger and Allow SomaLogic to Pursue Value-Enhancing Alternatives Madryn Asset Management, LP (collectively with its affiliates, "Madryn" or "we"), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. ("SomaLogic" or the "Company") (NASDAQ:SLGC), today issued the following statement regarding the proposed merger (the "Proposed Merger" or the "Transaction") with Standard BioTools Inc. ("Standard BioTools") (NASDAQ:LAB). We would like to thank the many sharehol

Glass Lewis Recommendation Emphasizes Strong Strategic Rationale and Thorough Process  ISS Reiterates Recommendation Following Public Commentary Recommendations Reiterate that Value Maximizing Transaction Is in the Best Interests of Stockholders; Board Urges Stockholders to Vote "FOR" the Transaction   BOULDER, Colo., Dec. 29, 2023 /PRNewswire/ -- SomaLogic, Inc. (NASDAQ:SLGC), a leader in proteomics technology, today announced that Glass Lewis & Co. ("Glass Lewis") has recommended that SomaLogic stockholders vote "FOR" the pending merger with Standard BioTools at the company's Special Meeting of Stockholders to be held on January 4, 2024. Together with the recommendation previously made by